Rephonic
Artwork for The Readout Loud

The Readout Loud

STAT
FDA
Eli Lilly
Novo Nordisk
Biotechnology
Pfizer
Gene Therapy
Covid-19
Duchenne Muscular Dystrophy
CRISPR
Vertex Pharmaceuticals
RFK Jr.
Sarepta Therapeutics
Moderna
Drug Pricing
Biotech
Obesity
Astrazeneca
Obesity Drugs
Cancer Treatments
Drug Development

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

PublishesWeeklyEpisodes409Founded8 years ago
Number of ListenersCategory
Business

Listen to this Podcast

Artwork for The Readout Loud

Latest Episodes

Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches?

We discuss all ... more

On this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.” That sounds alarmist, and it is in some respects, but ... more

On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the juicy conversations and insights, including BridgeBio CEO Ne... more

This week’s episode of “The Readout LOUD” is all about health politics.

We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he is leaving, which of his policies will stick, and what we know about his acting replacement, Kyle ... more

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

Recent Guests

Joe Betts-LaCroix
CEO of Retro Biosciences, longevity company backed by Sam Altman
Retro Biosciences
Episode: 402: Guarding biotech from China and big bets in longevity
Reid Waldman
CEO, Veradermics
Veradermics
Episode: 399: Hair-raising trial results, and Servier’s M&A wishlist
David Lee
CEO, Servier Pharmaceuticals US
Servier
Episode: 399: Hair-raising trial results, and Servier’s M&A wishlist
Preeti Hegde
Senior Vice President and Global Head of Research
Kite, a Gilead company
Episode: 399: Hair-raising trial results, and Servier’s M&A wishlist
Bryan Roberts
Partner at Venrock, investor in Kelonia
Venrock
Episode: 398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
Zach Roberts
Chief Medical Officer, Allogene Therapeutics
Allogene Therapeutics
Episode: 397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
Paul Oberstein
Pancreatic cancer expert from NYU Langone
NYU Langone
Episode: 397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
Rod Wong
Managing partner at RTW Investments, biotech investment fund
RTW Investments
Episode: 395: Biotech investors' plea to Trump, and a busy M&A week
Stelios Papadopoulos
Biotech veteran known as the godfather of biotech
Industry veteran (Biotech)
Episode: 393: A conversation with the 'godfather' of biotech

Hosts

Allison DeAngelis
Host of The Readout Loud
Adam Feuerstein
Co-host of The Readout Loud
Elaine Chen
Host/Co-host of The Readout Loud

Reviews

4.7 out of 5 stars from 588 ratings
  • Constructive Feedback on Episode 398

    Hey STAT Team - As a long time reader and biotech CEO, I wanted to pass on hopefully constructive feedback on your show in general and this specific episode. I really enjoyed hearing the inside scoop from Bryan Roberts on Kelonia and the Lilly deal. That was great. Please do more of that! In the constructive feedback category, the one thing that I would caution you on, both in this episode and others, is the trivial nature (joking, in fact) in how you handle very, very tough times for these comp... more

    Apple Podcasts
    3
    DP75007
    United Statesa month ago
  • David Olson

    Thoughtful and concise discussion about drug development processes. I found this illuminating

    and hopeful

    Apple Podcasts
    5
    Auldkirk
    United Kingdom6 months ago
  • Really informative and relevant

    Great coverage by the three hosts.

    Only area of improvement is if the audio editor can adjust the volume for all speakers to be equal because for some reason Elaine’s mic tends to be the loudest and I have to keep adjusting the volume for each speaker.

    Apple Podcasts
    4
    orange03$592
    United States6 months ago
  • Great pod!

    This is a great overview of the biopharm space with an engaging and fun style. I also like the unrelated chat amongst the team, particularly as a fellow fan of the Great British Bake Off, given this is an industry that can often take itself very seriously!

    Apple Podcasts
    5
    123etcetc
    United Kingdom7 months ago
  • Please reboot the old quality bar

    This podcast was a gold mine a few years back. Really miss that run you had. Adam is good but even he was better back when surrounded with higher caliber cohosts.

    Apple Podcasts
    3
    freedomtochoose
    United States9 months ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Informative and accessible biotech coverage with strong guest insights.
Can be polarizing at times; some listeners desire more neutrality and fewer in-jokes.
Engaging, high-credibility reporting from reporters and analysts.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#242
France/Business
Apple Podcasts
#119
Switzerland/Business
Apple Podcasts
#245
Singapore/Business
Apple Podcasts
#249
Israel/Business

Talking Points

Recent interactions between the hosts and their guests.

402: Guarding biotech from China and big bets in longevity
Q: What are the key challenges in moving aging biology from mouse models to human trials, and how is Retro addressing them?
She highlighted that mouse models often fail to perfectly predict human outcomes, and Retro is investing in better in silico models and robust in-house GMP capabilities, while acknowledging FDA expectations for animal studies and the need to balance speed with safety.
402: Guarding biotech from China and big bets in longevity
Q: Could you summarize the rationale behind Retro's focus on autophagy and aging biology as a therapeutic target?
The guest explained that autophagy is a first-in-class target with no current approved drug that specifically restores autophagy in stalled cells, and Retro aims to develop a safe, oral small-molecule that crosses the blood-brain barrier to address aging-related neurodegenerative processes, with phase one showing early signs of safety and potential efficacy.
400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles
Q: Daphne, welcome back to the podcast. Was it exhausting? Have you recovered? What was it like going through an IPO while personally involved in a major event?
It's been a crazy few weeks with a serious car crash, but the focus on the IPO and Seaport's mission helped keep things in perspective. Despite personal challenges, she emphasizes perseverance, team support, and staying committed to the mission of improving mental health through new medicines.
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
Q: Do you think the valuation and upfront payment reflect the risk profile of Kelonia's program?
The $3.25 billion upfront, with potential milestones, reflects the combination of pent-up demand for in vivo CAR-T platforms, the strategic fit with Lilly's pipeline, and the scalability upside if durability holds with larger patient populations, despite the early stage of data.
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
Q: Bryan, what was the key driver for Lilly's interest in Kelonia after Ash, and how did the negotiation unfold?
Lilly was drawn by the durable data showing deep responses and MRD negativity, the potential to expand an obesity-drug revenue franchise via a big CAR-T platform, and a favorable risk/return profile given their portfolio. Negotiations gradually ramped up over several months as Lilly built comfort with the team, data quality, and manufacturing.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About The Readout Loud

What is The Readout Loud about and what kind of topics does it cover?

The show breaks down biotech and health policy news with a lively, accessible style, pairing rapid-fire industry updates with in-depth interviews. Topics frequently center on FDA decisions, M&A activity, high-stakes trial results, and the economics of biotech, including telehealth, pricing, and reimbursement dynamics. A notable strength is the mix of seasoned reporters and industry executives, offering both investigative context and practical takeaways for people working in biotech PR, media, or sponsorships. The format's casual banter, strong reporting, and guest diversity make complex topics approachable while staying policy- and data-driven, which can help potential listeners decide if it fits their interest in biotech startups, pharma s... more

Where can I find podcast stats for The Readout Loud?

Rephonic provides a wide range of podcast stats for The Readout Loud. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to The Readout Loud and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does The Readout Loud get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for The Readout Loud, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for The Readout Loud?

Rephonic provides comprehensive predictive audience data for The Readout Loud, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does The Readout Loud have?

To see how many followers or subscribers The Readout Loud has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to The Readout Loud?

These podcasts share a similar audience with The Readout Loud:

1. BioCentury This Week
2. Biotech Hangout
3. The Long Run with Luke Timmerman
4. Business Of Biotech
5. The BioCentury Show

How many episodes of The Readout Loud are there?

The Readout Loud launched 8 years ago and published 409 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact The Readout Loud?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for The Readout Loud?

Rephonic pulls ratings and reviews for The Readout Loud from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for The Readout Loud?

Rephonic provides full transcripts for episodes of The Readout Loud. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on The Readout Loud?

Recent guests on The Readout Loud include:

1. Joe Betts-LaCroix
2. Reid Waldman
3. David Lee
4. Preeti Hegde
5. Bryan Roberts
6. Zach Roberts
7. Paul Oberstein
8. Rod Wong

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days